|

Field Trip Health Treating Depression With Ketamine-Assisted Therapy All Across North America (FTRP)

ByPsychedelic Spotlight



Ronan Levy, founder of Field Trip Health (NASDAQ: FTRP, TSX: FTRP), joins Psychedelic Spotlight’s Swati Sharma to discuss the widening research into psychedelic medicines and how they can be used to help patients in therapy.

Field Trip Health is one of the largest providers of psychedelic-assisted therapies globally and has distinguished itself as a leader in the emerging psychedelic industry with continued expansion and growing demand.

In this short interview, Ronan Levy discusses the company’s continuous expansion of their ketamine clinics, their drug development efforts, specifically for the company’s proprietary compound FT-104, and their efforts to normalize psychedelic medicines.

#FieldTripHealth #RonanLevy #PsychedelicMedicines

source

Similar Posts

  • Interview With Timothy Ko

    Listen, Podcasts

    CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.

  • We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??

    Listen, Videos

    In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.

    So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?

    Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
    However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
    In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Links:
    Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
    Montgomery-Asberg Depression Rating Scale (MADRS):
    https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale

    MAPS MDMA-PTSD Study:
    https://www.nytimes.com/2021/05/03/health/mdma-approval.html

    Comp 360 Open Label Study:
    https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html

    MindMed Psilocybin SSRI Study:
    https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #psilocybin #depression

  • MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

    Listen, Videos

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
    www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Join our Newsletter (scroll to the bottom of the page and sign up):
    https://psychedelicspotlight.com/

    Follow us on Twitter:
    The Psychedelic Investor: @PSYCBiz
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @psycbiz
    @psycspotlight

    ❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
    Stay tuned for more updates!

    In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.

    MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.

    Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.

    The results were very positive, though perhaps not paradigm shifting — yet.

    The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.

    The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.

    Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.

    Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”

    In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”

    Interested in reading the article? Click here: 👇

    MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
    https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/

    #MindMed #Anxiety #MNMD